As deliberated in my just previous article in this blog, Covid has been a watershed in several areas of pharma business. One such key area is its competition driven strategic business model. It aims to deliver significant value for a … Continue reading
Tag Archives: Patent
Setting A Cost Of Time That Patients May Gain From A New Therapy
Since quite some, an intense ongoing debate about setting a cost of time, often by a few months, that patients could possibly gain from a new therapy for complex diseases. The answer still remains elusive. Meanwhile, newer therapies for treating cancer, … Continue reading
Spirit Behind Drug Patent Grant: Secondary Patents: Impact on Drug Access
For more effective treatment against existing diseases, besides combating new or a more complicated form of existing ailments with precision, drug innovation is absolutely necessary and on an ongoing basis. This makes innovative drugs so important for the population, globally. … Continue reading
Will ‘Patent Thicket’ Delay Biosimilar Drug Entry in India?
Do pharma and biotech investors encourage companies indulging in ‘patent thicket?’ This question recently grabbed media headlines. On April 02, 2019, one such report brought out: AbbVie investors are calling for the Chair-CEO power split, flagging the CEO’s USD 4 million bonus payout, fueled … Continue reading
Is India A Success Story With Biosimilar Drugs?
How Indian generic companies are expanding, if not shifting their business focus on biosimilar and complex generic drugs, may be a current trend of general discourse – but the initiative is not a current one. This journey commenced decades ago … Continue reading
Innovation: Is Big Pharma Talking Differently?
“Nearly 2 billion people have no access to basic medicines, causing a cascade of preventable misery and suffering. Good health is impossible without access to pharmaceutical products.” The World Health Organization’s (WHO) ‘Access to Medicine’ report on ‘Ten years in … Continue reading
Pharma Brand Building: Criticality of Enhancing End-To-End Customer Experience
In today’s fast-changing world, the types of medicines being developed, the way technology contributes to health, and how the value of health care is calculated, are all undergoing a metamorphosis. A wave of cell and gene therapies are bending the definition … Continue reading
Why MNC Pharma Still Moans Over Indian IP Ecosystem?
Improving patient access to expensive drugs, paving the way for entry of their cheaper generic equivalents, post patent expiry, and avoiding evergreening, is assuming priority a priority focus area in many countries. The United States is no exception, in this … Continue reading